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Basal progenitors (BPs), including intermediate progenitors and basal radial glia, are gener-
ated from apical radial glia and are enriched in gyrencephalic species like humans, con-
tributing to neuronal expansion. Shortly after generation, BPs delaminate towards the
subventricular zone, where they further proliferate before differentiation. Gene expression
alterations involved in BP delamination and function in humans are poorly understood. Here,
we study the role of LGALS3BP, so far known as a cancer biomarker, which is a secreted
protein enriched in human neural progenitors (NPCs). We show that individuals with
LGALS3BP de novo variants exhibit altered local gyrification, sulcal depth, surface area and
thickness in their cortex. Additionally, using cerebral organoids, human fetal tissues and mice,
we show that LGALS3BP regulates the position of NPCs. Single-cell RNA-sequencing and
proteomics reveal that LGALS3BP-mediated mechanisms involve the extracellular matrix in
NPCs’ anchoring and migration within the human brain. We propose that its temporal
expression influences NPCs’ delamination, corticogenesis and gyrification extrinsically.
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Cortical development is a tightly regulated process in whichneural progenitor cells (NPCs) in the ventricular (VZ) andsubventricular zones (SVZ) generate cortical neurons1.
Although the basic molecular and cellular mechanisms governing
corticogenesis in mammals are shared, the substantial differences
regarding the shape and size of the cortex between primates (and
in particular humans) and other mammals, suggest that specific
changes have occurred during evolution2–5. Dysregulation of
these mechanisms as a consequence of genetic alterations causes
cortical malformations in humans, such as microcephaly, lissen-
cephaly, and periventricular heterotopia (PH)6–11.
One possible explanation for the massive increase in cortical
size in primates was proposed to be the expansion of basal pro-
genitors (BPs), namely intermediate progenitors (IPs) and basal
radial glial cells (bRGs). Generated from apical radial glial cells
(aRGs) in the VZ, both types of BPs delaminate to the inner and
outer SVZ (iSVZ and oSVZ, respectively). IPs perform mainly
symmetric neurogenic divisions but in humans, it was shown that
they also have a proliferating capacity12,13, while bRGs undergo
several rounds of proliferating divisions before terminal differ-
entiation. bRGs are found in higher numbers in gyrencephalic
compared to lissencephalic species and thus, have been proposed
to be central for the generation of gyri and sulci of the cerebral
cortex4. Thereby, both BPs contribute to the increased number of
neurons found in the human cortex14–16.
Significant differences between the transcriptome of NPCs in
the germinal zones generating gyri compared to those generating
sulci have been demonstrated17, and consequently it was pro-
posed that certain genes, which are newly evolved or whose
expression and/or function are altered in gyrencephalic species,
can control the delamination and function of BPs. Such factors
would also be hypothesized to mediate the expansion of the
cerebral cortex and hence contribute to gyrification. Numerous
genes have already been implicated in the generation of BPs
facilitating gyrification15,18–22 with recent insight also outlining a
role for mechanical forces23. The extracellular matrix (ECM) has
also been implicated in both neocortical expansion and cortical
folding18,24–26. However, the nature of the mechanistic connec-
tion between the molecular, cellular, and mechanical factors
influencing the generation and function of BPs in gyrification
remains largely unknown27.
To this end, we studied the role of galectin-3 binding protein
(LGALS3BP), a secreted protein that interacts with several
members of the ECM such as integrins, fibronectins, galectins,
laminins, and tetraspanins28–31, and has been well studied
in cancer biology. Recently, it was shown that the LGALS3BP
mRNA, although almost undetectable during mouse
corticogenesis32, is enriched in human NPCs18,24 and bRGs33–35.
Here we show that LGALS3BP is enriched in human NPCs and
its function is of great importance in human corticogenesis since
changes in local gyrification are shown in individuals with
de novo genetic variants in LGALS3BP. We propose that
LGALS3BP is secreted via extracellular vesicles (EVs) and its
interaction with the ECM, collagens, and tetraspanins regulates
apical anchoring of aRGs, leading to BP delamination, and con-
sequently cortical folding in humans.
Results
Expression of LGALS3BP in human NPCs. Recently, it was
proposed that the niche where NPCs and neurons are generated
and function is essential for proper cortical development, and that
mechanical forces, as well as specific extracellular environment,
may contribute to human cortical development25,36. However,
little is known so far on the human-specific mechanisms reg-
ulating corticogenesis. This lack of information may also be
because the most commonly used model for corticogenesis is the
mouse, a lissencephalic species, and thus it becomes apparent that
the use of other models is necessary. Towards identifying human-
specific niche regulators and human-specific molecular and cel-
lular mechanisms regulating human NPC generation and differ-
entiation, we hypothesized that genes that are highly expressed in
the developing human cortex (where BPs are expanded) but are
with a reduced expression in mice (where BPs are restricted),
would be prominent regulators of such processes. Thus, we
focused on the gene LGALS3BP, whose mRNA according to
previous work is expressed at high levels in aRGs, IPs, and bRGs
in humans, is downregulated in human neurons (Supplementary
Fig. 1a) and concurrently is almost undetectable in the developing
mouse brain18,24,32. Additionally, LGALS3BP mRNA expression
in the developing ferret brain is twofold higher in the neurogenic
regions that form gyri, compared to those generating sulci17, and
its expression is increased during the evolution of the brain from
macaque to chimpanzee and humans37.
To gain insight into the temporal and spatial localization of
LGALS3BP, we generated human induced pluripotent stem cell
(iPSC)-derived cerebral organoids (COs)38 (Supplementary
Fig. 1b) and examined LGALS3BP expression longitudinally over
COs development. LGALS3BP mRNA has its peak of expression
shortly after the known aRG marker PAX6 and before BP
markers like EOMES and HOPX (Fig. 1a), a pattern which is also
observed in the human fetal brain as shown from the BrainSpan
dataset (https://www.brainspan.org/). To further investigate the
LGALS3BP gene expression at the single-cell level in COs, we
performed single-cell RNA-sequencing (scRNA-seq) in 60 days’
(60d) COs and showed that LGALS3BP is enriched in progenitor
cells but is progressively reduced upon neuronal differentiation
(Fig. 1b and Supplementary Data 1). These data were confirmed
by qPCRs performed in iPSC-derived NPCs and neurons in 2D
(Supplementary Fig. 1c). In addition, we performed in situ
hybridization in COs at 30d, 50d, and 60d and showed that
LGALS3BP is expressed in a salt and pepper fashion in NPCs,
suggesting its upregulation in a specific subpopulation of
progenitors (Fig. 1c–e and Supplementary Fig. 1d–i’).
LGALS3BP was shown to be a component of the ECM in
cancer tissues, thus, to investigate whether LGALS3BP is
expressed in COs at the protein level and whether it is secreted
from NPCs and neurons, we have analyzed the full proteome (full
lysate) and secretome (culture medium) of control COs at 60d, a
developmental stage where mRNA of LGALS3BP is highly
present. This analysis confirmed the protein expression and
secretion from human cortical cells (Supplementary Data 2 and
3). Additionally, immunofluorescence performed in mice, COs, or
in human fetal cortical tissues revealed specific dotty staining of
LGALS3BP (highlighted with arrows) in humans but not in mice
(Fig. 1f–q and Supplementary Fig. 1j–n), which is in line with its
secretion and presence in vesicles as recently reported39–41, and
that its expression is mainly in the neurogenic zones of the
human developing cortex, namely the VZ, iSVZ, and oSVZ.
Moreover, the LGALS3BP+ punctae are in close correlation with
the progenitor marker SOX2 and not with the neuronal marker
NEUN (Fig. 1o–q and Supplementary Fig. 1g–i). Collectively,
these data suggest that LGALS3BP has a very dynamic expression
and localization both at the cellular and temporal level during
human cortical development. We, thus, hypothesized that it could
shape the extracellular niche of human NPCs, contributing to the
dynamics of human NPCs’ transition and influence the process of
gyrification of the human cerebral cortex.
Individuals with LGALS3BP variations have cortical changes.
Expression of LGALS3BP is enriched in the developing brain in
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humans and assessment of data from control individuals (derived
from the NHLBI-ESP6500 dataset) demonstrate that the coding
region of LGALS3BP is depleted of genetic variation in human
populations with metrics placing it within the top 10% of genes
intolerant to non-conservative changes with a specific Residual
Variance Intolerance Score (RVIS) of 8.9%42. Therefore, we
hypothesized that variants within LGALS3BP could result in
defective neurogenesis in humans. The enrichment of loci with
rare de novo variants in individuals with the neurodevelopmental
condition called periventricular nodular heterotopia (PH)
was recently described, suggesting the involvement of these genes
in the pathogenesis of this disease11,43. In this study11, one
individual with a de novo missense variant in LGALS3BP (indi-
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diagnosed with developmental delay, autism, dysarthria, ataxia,
and focal seizures at 3 years of age. His MRI demonstrated PH in
the right temporal horn and within the contralateral peri-
hippocampal region, close to a rounded and under-rotated left
hippocampus in addition to cerebellar vermian dysgenesis with
an accompanying mega cisterna magna (Supplementary Fig. 2a,
b–d). Two further individuals with de novo missense variants in
LGALS3BP (individual 2, c.880 C > T [p.Glu294Lys]; RefSeq
NM_005567.4; and individual 3, c.1580 T > C [p.Glu527Gly];
RefSeq NM_005567.4) were identified within the Deciphering
Developmental Disorders (DDD) study (n= 1133)44 (Supple-
mentary Fig. 2a). Phenotypically, individual 2 was diagnosed with
prenatal onset microcephaly (occipitofrontal head circumference
−5.5 SD) and global neurodevelopmental delay. An MRI
demonstrated a primitive sulcal pattern and a lack of folding of
the operculum. There were no seizures or radiological evidence
for PH. No clinical data could be ascertained for individual 3. All
three de novo variants in these individuals lie within the most
intolerant sub-region of LGALS3BP45—namely the exon 5
(Supplementary Fig. 2e)—suggesting that they may be function-
ally disruptive, and thereby contributing causally to the neuro-
developmental phenotypes observed. Although individuals 1 and
2 were described with different developmental diseases, by ana-
lyzing the morphology of their brains via brain MRI imaging with
age-matched morphometric analysis46,47, we noticed similar
defects in the formation of their brains. In particular, cluster
analysis in both individuals revealed changes in cortical thickness,
local gyrification index (LGI), surface area, and sulcal depth
(Fig. 2a, a’), which, even though were not perfectly overlapping in
the brain regions of the two individuals, suggest that overall
LGALS3BP variants affect cortical formation.
To gain insight into the mechanisms which were affected in the
clinically observed LGALS3BP genetic variants, by using CRISPR/
Cas9 genome editing we generated iPSC lines carrying either the
variant found in individual 1 (p.E370K, from now on referred to
as E370K) in heterozygosity to mimic exactly the situation
observed in individual 1 or a two base-pair deletion before the
position of the variant in this individual, which resulted in a
frameshift (p.Y366Lfs*443, from now on referred to as Y366Lfs)
in homozygosity to avoid a potential mask of phenotype due to
the existence of a functional allele in the case of the heterozygous
E370K (Supplementary Fig. 2f and Supplementary Data 4). We
prioritized individual 1 because individual 2 was only 1 year old
when imaged which, due to incomplete myelination, makes it
difficult to properly assess the cortical thickness, LGI, surface
area, and sulcal depth. We generated COs derived from isogenic
control and from the genetically edited iPSCs, E370K, and
Y366Lfs, which show reduced LGALS3BP expression compared
to control (Supplementary Fig. 2g–j). We then monitored their
development at different stages. During the early stages of
development, genetically edited COs exhibited a delay in their
growth as indicated by their smaller perimeter which, however,
was normalized within a few days (Supplementary Fig. 2k–q).
Also, no significant changes were observed either in the total
number of progenitors, PAX6+, SOX2+, and HOPX+ popula-
tions (Fig. 2b, c and Supplementary Fig. 2r–t), or in the total
number of neurons, DCX+ and NEUN+ populations (Supple-
mentary Fig. 2u–ab’). However, we observed differences in the
distribution of NPCs. A higher number of NPCs performed
mitosis at the apical surface in proximity to the ventricles
compared to controls (Fig. 2d–h). Interestingly, we noticed that
both general RG markers, such as FABP7, and bRG markers, such
as HOPX, had different distributions in the mutant COs
compared to controls. Namely, we observed increased number
of FABP7+ cells located within the VZ (Fig. 2i–l) and an
increased number of ventricles containing more than 10 HOPX+
cells localized apically and demonstrating an apical accumulation
in the genetically edited COs (almost 70% and 75% in the E370K
and the Y366Lfs mutant COs, respectively, compared to 30% in
control COs) (Fig. 2m–p). This suggests that a higher number of
NPCs, either apical or basal, may divide at apical positions within
the mutant backgrounds.
Since individual 1 also exhibits PH, we explored the idea that
PH could be caused by the misplacement of NPCs. To test this
hypothesis, we assessed the neuronal populations within the
mutant COs and found that, although their total number was
unaffected, there was a substantial number of neurons positioned
in the VZ (Supplementary Fig. 2u–w’, z–ab’). We, therefore,
quantified the percentage of ventricles that featured ectopic
neurons in the VZ and found that almost 60% and 75% of the
E370K and Y366Lfs mutant ventricles, respectively, had neurons
within the progenitor zone in contrast to 28% in the isogenic
control (Supplementary Fig. 2ac). These percentages were very
similar to the previously quantified ventricles with non-
delaminated (apical) HOPX+ BPs (Fig. 2p) and could explain
the morphological changes observed in the individuals with
LGALS3BP variants. Apart from the neuronal misposition, we did
not observe any other cortical defects even though both
individuals 1 and 2 exhibit changes in the LGI, sulcal depth,
and cortical surface. This is not surprising since gyrification
cannot be assessed using COs since there is no normal folding in
the cortical plate of COs—a limitation of this model system.
Nevertheless, many of the changes observed in the two
individuals are located in the deep areas of the MRIs which
could reflect the ectopic neurons. All the above suggest that the
different mutations in the exon 5 of the LGALS3BP gene or its
complete loss impact its proper expression and results in changes
in the development of the neuroepithelium in the human cortex.
To determine whether LGALS3BP is sufficient to influence
human neurogenesis by changing their number or by misplacing
NPCs and neurons during development, we manipulated its
expression in control COs and organotypic slices of the human
fetal brain (Supplementary Fig. 3a, a’). Overexpression of
LGALS3BP via electroporation in COs at 40d was chosen for
further analysis because this is a stage before the peak of
LGALS3BP expression and before the significant increase of the
Fig. 1 LGALS3BP expression in human cortical progenitors. a Bulk RNA-sequencing data performed in COs at different stages. LGALS3BP has a peak of
expression after apical progenitor marker PAX6 and prior to basal progenitor markers EOMES and HOPX. Data are shown as mean ± SEM, batches= 3,
organoids= 3. Statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple comparison test, *p < 0.05, **p < 0.01,
****p < 0.0001. In (a), p= 0.0026 in ctrlvsY366Lfs. b Violin plots from scRNA-seq data performed in 60d control COs showing LGALS3BP mRNA
expression levels in RGs, IPs, and N, batches= 1, organoids= 2, cells= 9290. c–e In situ hybridization depicting mRNA expression of LGALS3BP in 30d,
50d, and 60d control COs. Arrows show basally located LGALS3B+ cells, batches= 1, organoids= 3, ventricles= 3. f–h Micrograph of control CO sections
immunostained with specific LGALS3BP antibody. i–q Micrograph of human fetal cortical sections immunostained as depicted in the panels at GW14 (i–k)
and 20 (l–q). Arrows show LGALS3BP+ cells. Scale bar: 30 μm in (c–h), 500 μm in (i–n), and 100 μm in (o–q). See also Supplementary Fig. 1.
Abbreviations: d: days, RG: radial glial cells, IP: intermediate progenitors, N: neurons, GW: gestational week, VZ: ventricular zone, iSVZ: inner subventricular
zone, oSVZ: outer subventricular zone, IZ: intermediate zone, CP: cortical plate.
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BPs (EOMES+ IPs and HOPX+ bRGs) in the CO cultures (as
shown in Fig. 1a). Analysis at 4 days later (4dpe, days post
electroporation) showed that LGALS3BP overexpression changed
the morphology of NPCs from a radial-bipolar to a more
multipolar shape and led to the loss of their apical attachment
(Supplementary Fig. 3b, c). Also, overexpression of LGALS3BP in
COs at 40d resulted in a reduced number of SOX2+ apical NPCs
in the VZ (Supplementary Fig. 3d–g’, p), increased number of
HOPX+ BPs (Supplementary Fig. 3h–k’, q, r), and increased
neuronal differentiation suggesting a premature differentiation in
these COs (Supplementary Fig. 3l–o’, s). Next, to further assess
the function of LGALS3BP in human NPCs, we overexpressed
LGALS3BP in human fetal brain sections obtained from
gestational week (GW) 16 fetuses and analyzed the number of
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SOX2+ cells in the oSVZ 7dpe for assessing mainly the number
of bRGs48 (Supplementary Fig. 3t–z). Similar to what was
observed in COs, LGALS3BP overexpression resulted in an
increased number of oSVZ SOX2+ NPCs—basally located NPCs.
All the above pointed out that dysregulation of LGALS3BP either
by mutation or by overexpression influences the position of
human NPCs in the different neurogenic zones, the VZ and SVZ.
One of the mechanisms that promote the generation of BPs
from aRGs and their translocation to the SVZ is the detachment
from the apical side and the delamination. Since mutation or
overexpression of LGALS3BP affects the position of NPCs, we
examined whether LGALS3BP has a role in the apical anchoring
and we analyzed the apical belt in COs. Immunostaining for β-
catenin and F-actin (phalloidin immunostaining) was performed
after LGALS3BP overexpression in COs at 4dpe (Fig. 3a–h). At
the site of electroporation, but not in adjacent regions or control
electroporation, β-catenin and F-actin expression were dramati-
cally reduced (green and red arrowheads, respectively, in
Fig. 3a–h) in almost 70% of the ventricles in the COs analyzed
(Fig. 3i). Interestingly, in some cases, cells were submerged to the
ventricular space (Fig. 3c–d) possibly due to the loss of the apical
membrane integrity. In contrast, the thickness of the apical belt in
both E370K and Y366Lfs genetically edited COs was strongly
increased compared to controls as indicated by several apical
junction markers, such as F-actin (Fig. 3j–l’), β-catenin
(Fig. 3m–o), PALS1 (Fig. 3p–r), pan-cadherin (Fig. 3s–u), and
the cilia protein ARL13B, as cilia are localized apically in RGs and
therefore is an indirect indicator of the apical endfeet of aRGs
(Fig. 3v–x). Quantification of the thickness of the apical belt based
on some of its major components, namely the cytoskeleton (F-
actin), members of the apical polarity complex (PALS1), and
members of the adhering components (pan-cadherin), showed
that the apical belt in mutant COs is almost three times thicker
than in control COs (Fig. 3y–aa). Given that LGALS3BP was
shown to cause centriolar accumulation49, we also tested cilia
dysregulation in mutant COs. Despite the increase in the total
number of cilia (Fig. 3a, b), which can be explained by the
increased number of progenitors found in the VZ of the mutant
COs as it was previously described, we also observed a reduction
in their length (Fig. 3a, c). We did not observe any further
dysregulation of cilia like disorientation or increased number of
cilia per cell suggesting no major malfunction of cilia. Taken
together, forced local expression of LGALS3BP in aRGs resulted
in disorganization of the apical belt, which we propose as the
cellular mechanism leading to increased delamination of NPCs.
In contrast, LGALS3BP mutations resulted in the thickening of
the apical belt and the prevention of delamination of NPCs. This
effect of LGALS3BP on the apical anchoring may also explain the
indirect mislocalization of neurons observed in mutant COs and
individuals with LGALS3BP genetic variants.
Mutant COs reveals cell non-autonomous function. To deci-
pher the molecular mechanisms through which LGALS3BP
modulates human neurogenesis, NPC distribution, and gyrifica-
tion, we firstly performed a whole-proteome analysis of the lysate
isolated from the control and genetically edited COs in order to
discriminate any changes in the protein levels between the three
conditions—control, E370K, and Y366Lfs COs (Fig. 4a and
Supplementary Data 2). We chose to perform this analysis in COs
at 60d which is a time point when LGALS3BP expression shows a
significant increase, while there is no significant increase of the
BP markers (Fig. 1a). First, we validated that the levels of
LGALS3BP in the mutant COs are reduced (Fig. 4a), and that the
LGALS3BP levels are less reduced in the E370K COs (hetero-
zygous line) than in the Y366Lfs COs (homozygous line). Then,
the proteomic profile of the E370K and Y366Lfs COs was assessed
by mass spectrometry. No significant changes between E370K and
Y366Lfs COs were observed (Fig. 4a and Supplementary Data 2)
and for that reason, we further analyzed the data combining the
proteome from the two different mutant COs. GO Term analysis
of the upregulated and downregulated proteins identified,
revealed that the biological processes that were mainly dysregu-
lated were those related to neurogenesis, neuron differentiation,
and neuron development (Fig. 4b), which comes in line with the
changes in cortical thickness and LGI in the 2 individuals with
LGALS3BP genetic variants found and the phenotype observed
upon manipulation of LGALS3BP in COs. Another process that
was found highly dysregulated from this analysis was related to
cellular component organization, cellular component biogenesis,
and cellular component morphogenesis (Fig. 4b). Interestingly,
the three highest cellular components that were found dysregu-
lated were the extracellular organelle, extracellular vesicles, and
extracellular exosomes, speaking for changes in the extracellular
environment of these COs (Fig. 4b). For that reason, we then
focused on the protein differences in the extracellular environ-
ment of the genetically edited COs by performing secretome
analysis (mass spectrometry analysis performed on the proteins
secreted in the culture medium; Fig. 4c and Supplementary
Data 3). First, we observed that the two mutant forms of
LGALS3BP were very little secreted because of their reduced
initial expression levels and/or alterations in secretion. Second,
similar to what was observed in the proteome, the two mutants
did not differ significantly from each other and were further
processed together (Fig. 4c). We then examined the most sig-
nificant biological and cellular component processes that were
dysregulated in the mutant COs and, in line with the proteome,
Fig. 2 Genetic Variants within LGALS3BP in humans associated with cortical malformations. a, a’ Morphometric analysis of the MRIs of individual 1 (a)
and 2 (a’) showing changes in cortical thickness, local gyrification index, surface area and sulcal depth in different positions of the cortex. Statistical
analysis of morphometric data was performed by a two-tailed paired t-test which compares each individual with a template obtained by averaging 8 age-
matched controls. Cortical maps were clustered and corrected for multiple comparisons. b, c FACS plots and respective quantification depicting the sorting
of PAX6+ (b) or HOPX+ (c) cells in 60d old control, E370K, and Y366Lfs mutant COs. The total proportion of the apical and basal progenitor cells is not
changed in mutant COs. Data are shown as Z-scores ±SEM, batches= 2, organoids= 9. d–f, i–k’,m–o”Micrographs of sections of 60d control, E370K, and
Y366Lfs mutant COs immunostained for PH3 (d–f), FABP7 (i–k’) or HOPX (m–o”). Arrows indicate the PH3+, FAPB7+, or HOPX+ cells which retain the
apical contact with the ventricular zone. The apical and basal processes of the HOPX+ cells as indicated by the staining (arrows along the length of the
processes) show the cells which should typically lose their apical processes, they tend to retain them and keep the attachment to the apical membrane in
the mutant COs. g, h, l Quantification of the apically (g) or basally (h) located PH3+ cells and the number of FABP7+ cells within the VZ normalized to the
apical membrane length (l) are shown as Z-scores ±SEM. Statistical significance was based on two-sided Mann-Whitney U test **p < 0.01, ***p < 0.001,
****p < 0.0001, batches= 2, organoids= 6, ventricles= 20. In (g), p= 0.0026 in ctrlvsY366Lfs. In (l), p= 0.0005 in ctrlvsE370K, p= 0.0012 in
ctrlvsY366Lfs. p Quantification of the percentage of ventricles having non-delaminated HOPX+ cells. Statistical analysis was based on one-tailed exact
binomial test **p < 0.01, ***p < 0.001, batches= 2, organoids= 6, ventricles= 15. In (p), p= 0.0023 in ctrlvsE370K, p= 0.0004 in ctrlvsY366Lfs. Scale bar:
30 μm. See also Supplementary Fig. 2. Abbreviations: CTRL: control, d: days.
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we observed that the extracellular structure organization, ECM,
extracellular vesicles, and vesicle lumen turned up. All the above
are of great importance taking also into account that LGALS3BP
is secreted via vesicles in the size of exosomes and shows that the
extracellular environment is influenced by the expression/secre-
tion of LGALS3BP, indicating its cell non-autonomous role in
human brain development.
To dissect the specific cell type(s) affected in the COs, we
performed scRNA-seq analysis in control, E370K, and Y366Lfs
COs. SPRING and clustering analysis of the RSS37 integrated
scRNA-seq-data-identified cells from all different areas in the
developing brain (Fig. 4e–g, Supplementary Fig. 4a–d, and
Supplementary Data 1), as expected when using intrinsic
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cells were aligned on a developmental pseudotime, which revealed
the progression from cortical RGs via IPs to neurons (Fig. 4f and
Supplementary Fig. 4c, d). This differentiation trajectory was
preserved in all three genotypes (control, E370K, and Y366Lfs).
Together, this suggests that basic developmental processes were
maintained in LGALS3BP mutant COs. However, when compar-
ing the proportion of each cell type in control and mutant COs
(Fig. 4h and Supplementary Fig. 4b, e), we noticed that (i) the
majority of the mutant CO cells were mainly with dorsal identity
and (ii) the bRG population was strikingly less represented in the
mutant COs (135 bRGs in control, 4 in Y366Lfs, and 15 in
E370K), while the other cortical cell states were represented in
similar numbers (Fig. 4h).
Next, we performed differential expression (DE) analysis in
cortical RGs, IPs, and neurons, respectively, in order to identify
transcriptional differences in these cell populations. The geneti-
cally edited cortical CO cells showed very similar gene expression
signatures with very few genes differentially expressed between
themselves (Supplementary Fig. 4f–i), consistent with the
previous observation of a lack of differences in the cellular
phenotype, the proteome, and the secretome. We, therefore,
pooled the cells derived from E370K and Y366Lfs COs (mutant
cells, MUT). We identified genes that were up- and down-
regulated in mutant compared to control CO cell populations
(Supplementary Fig. 4f, j and Supplementary Data 1). Several
genes were commonly differentially expressed, such as general RG
markers—FABP7, ID4, MDK, PTPRZ1, and PTN—which were
dysregulated specifically in mutant RGs (Supplementary Fig. 4k),
suggesting that the RG population was mainly affected in the
mutant COs. In addition, we observed that loci involved in
NOTCH (HES1, HES5, HEY1, DLL1) and WNT (GSK3B,
WNT7B) signaling pathways were differentially regulated in
mutant cells (Supplementary Fig. 4k). These data potentially
explain the role of LGALS3BP in neuronal differentiation of
human NPCs and the non-cell-autonomous phenotype observed
on the mislocalization of aRGs vs BPs. In addition, it was recently
shown that several Wnt proteins have a different expression
pattern throughout development and specifically, Wnt7b is
important to respecify apical progenitors in mice changing their
fate restrictions51, thus, we speculate that changes in the
transcriptional profile of LGALS3BP mutant cells may affect
their specification and fate, and consequently their position.
Finally, focusing only on the RG population, we performed GO
analysis for the most significant and enriched biological processes
(Fig. 4i). Similar to the analysis in proteome and secretome, the
highest processes affected specifically on RGs were related to
cellular component organization, cellular process, and cellular
localization. In particular, cellular component dysregulated
processes were related to extracellular exosomes, extracellular
organelle, and extracellular vesicles (Fig. 4i). On the contrary,
similar analysis on the DEGs in IP and N did not reveal any
relevance in extracellular exosomes. Taken together, our data
suggest that manipulation of LGALS3BP expression in human
brain cells changes the extracellular niche of the cells, and more
importantly that the major cell type affected are the RGs.
Secreted factors rescue mutant COs’ phenotype. Having estab-
lished that proper LGALS3BP expression influences the extra-
cellular environment of human RG which regulates their
delamination and in turn human cortical development, we
wanted to demonstrate the specific action of LGALS3BP on these
processes and tested whether LGALS3BP alone could rescue the
phenotype observed in the mutant COs. To that end, we over-
expressed LGALS3BP in control, E370K, and Y366Lfs COs and
assessed the integrity of the apical belt and the neuronal posi-
tioning (Supplementary Fig. 5a–g, h–n). Upon LGALS3BP over-
expression, the apical belt of the mutant COs clearly exhibited a
patchy morphology in the electroporated area (Supplementary
Fig. 5g). In addition, the forced expression of LGALS3BP in
mutant COs could fully rescue the ectopic neuronal phenotype
(Supplementary Fig. 5n), suggesting that proper expression of
LGALS3BP is important for the positioning of neurons in the
developing human cortex and elucidate the phenotype observed
in individuals with LGALS3BP variations or mutant COs.
Then, taking into account the major differences in the
extracellular environment observed at the protein level and the
dysregulated genes in human RGs, we sought to test the extrinsic
influence of LGALS3BP and specifically whether the secreted
environment in control COs can influence the development of
the genetically edited COs. To that end, E370K or Y366Lfs COs
were treated with control COs’ medium from 16 to 60d of culture
(Fig. 5a). The medium switch was performed every day from COs
generated from the same batch and the comparison was
performed with COs cultured in their own medium. Analysis of
the number of apically divided PH3+ cells (Fig. 5b–d), the
thickness of the apical belt based on the phalloidin staining
(Fig. 5e–g), and the number of ventricles with ectopic NEUN+
cells (Fig. 5h–j) showed that medium generated from control COs
can completely rescue the phenotype observed in mutant COs.
All the above strongly suggest that the secreted environment of
human RGs is of great importance for their proper localization
and proper human cortical development.
LGALS3BP regulates location of NPCs and cortical develop-
ment. Given that the developing mouse cortex has a limited
amount of BPs, is not as expanded as the human cortex and lacks
folds, and that Lgals3bp exhibits negligible expression in the
developing mouse cortex18,32,52, we next investigated whether
forced expression of the human gene isoform of LGALS3BP can
promote the delamination of aRGs into BPs in the mouse model
in vivo. Our hypothesis was based on the fact that previous
Fig. 3 LGALS3BP controls apical anchoring of human progenitor cells. a–h Micrographs of sections of control COs immunostained as indicated in
the panels after electroporation of control or LGALS3BP at day 40 and analyzed 4dpe and immunostained as indicated in the panels (phalloidin in (a–d),
β-catenin in (e–h)). Green arrows depict the electroporated area and red arrows the adjacent area. White boxes indicate the area which is zoomed-in in
corresponding pictures. j–x Micrographs of sections of day 60 control, E370K, and Y366Lfs mutant COs immunostained as indicated in the panels
(phalloidin in (j–l’), β-catenin in (m–o), Pals1 in (p–r), Pan-cad in (s–u), Arl13b in (v–x)). White boxes indicate the area which is zoomed in in corresponding
pictures. i Quantification of the percentage of COs with intact or patchy apical junction upon overexpression of LGALS3BP depicted in (a–g’). Data were
statistically analyzed with one-tailed exact binomial test, ****p < 0.0001, batches= 2, organoids= 6, ventricles= 12. y–ac Quantification of the phalloidin
(y), PALS1 (z) or PAN-CAD (aa) thickness depicted in (j–u) and cilia number (ab) and length (ac) depicted in (v–x). Data in (z–ac) are shown as Z-scores
±SEM, statistical significance was based on the two-tailed Mann-Whitney U test *p < 0.05, ***p < 0.001, ****p < 0.0001, batches= 2, organoids= 6,
ventricles=12. In (z), p= 0.0003 in ctrlvsE370K, p= 0.0184 in ctrlvsY366Lfs. In (aa), p= 0.0271 in ctrlvsE370K, p= 0.0302 in ctrlvsY366Lfs. In (ac),
p= 0.0012 in ctrlvsE370K. Scale bar: 30 μm. See also Supplementary Fig. 3. Abbreviations: CTRL: control, dpe: days post electroporation, d: days, PAN-
CAD: PAN-CADHERIN.
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publications have shown that other human-specific or -enriched
genes may be able to promote increased basally located pro-
genitors and cortical folding in mice even though this normally
does not happen15,18,21. To that end, we electroporated
LGALS3BP in the developing mouse cortex at embryonic day 13
(E13) and analyzed the embryos at E16 (3dpe). The distribution
of GFP+ electroporated cells did not change when LGALS3BP
overexpression was compared with control (Supplementary
Fig. 6a–c), suggesting that the presence of the human gene caused
no major morphological differences during this time window. We
did, however, observe differences in the relative position of the
different NPC types. Specifically, Pax6+ aRGs, Hopx+ (expressed
in aRGs in mice and in bRGs in humans), and Tbr2+ BPs were
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under control conditions (Fig. 6a–d, f–i, k–n). Quantification of
the total number of Pax6+, Hopx+, and Tbr2+ cells showed no
differences (Supplementary Fig. 6d–f). However, their percen-
tages found in the VZ (BinA) were significantly smaller, while the
percentage found basally in the SVZ in the intermediate zone (IZ,
BinC) was doubled or more (Fig. 6e, j, o). Interestingly, many
were not GFP+ indicating a cell non-autonomous phenotype.
This suggests that in these cortices an oSVZ-like territory was
formed, where bRG-like cells were found, reminiscent of obser-
vations in gyrencephalic species such as humans.
In addition, we also observed a small but obvious change
(bend) in the band of Ctip2+ deep layer cortical neurons in 50%
of the mice analyzed (Supplementary Fig. 6g–m). This curvature
was located basally to the ectopic Pax6+ progenitors (Supple-
mentary Fig. 6g–l). We, therefore, hypothesized that this could be
the initiation of a rudimentary fold in an otherwise smooth
mouse cortex. To test the hypothesis that the newly formed
oSVZ-like territory contains functional bRGs, an additional
analysis was performed at 6 and 13dpe. Forced expression of
LGALS3BP for 6d in vivo promoted the expansion of the cortex
including the generation of rudimentary gyri and sulci on the side
of electroporation, while the contralateral hemisphere was
completely smooth. Interestingly, these rudimentary folds were
composed of both deep (Tbr1+) and upper (Satb2+) layer
neurons and were maintained in the developing cortex until
postnatal stage P7, 13dpe (Fig. 6p–w and Supplementary
Fig. 6n–q). The expansion promoted upon LGALS3BP over-
expression as found in 62% of the electroporated brains, 24% of
which were classified as major folds and 48% as minor (Fig. 6x).
The formation of folds was not observed in all the animals that
were analyzed which may suggest that intrinsic mouse mechan-
isms may mask the phenotype, especially at later stages as the
overexpression of LGALS3BP is transient, a possible consequence
of the limitation of the mouse model to study folding. However,
we observed the cortical expansion from as early as 3–13dpe
significantly changing the way that the mouse cortex develops
in vivo. To support these data and to investigate whether these
folds have typical morphology as in the human cortex, we
investigated the integrity of the basement membrane by
immunostaining for laminin, an essential component of the
basement membrane, and found that it was intact and
encompassing the newly generated fold (Supplementary Fig. 6r–t’)
in most of the animals analyzed.
To investigate whether the LGALS3BP genetic variants
influence the position of NPCs in vivo in mice or if this occurred
only in a context where LGALS3BP is endogenously expressed,
namely in the developing human cortex, we next investigated
whether these variants are sufficient to recapitulate the phenotype
observed upon overexpression of the wild-type form of
LGALS3BP. To that end, we electroporated the LGALS3BP
variants found in individuals 1 and 2, E370K, and p.E294K
(referred to as E294K), respectively, in the developing mouse
cortex at embryonic day 13 (E13) and analyzed the embryos at
E16 (3dpe). Immunostaining against LGALS3BP showed that all
the variants, wt, E370K, and E294K, are expressed in the
developing mouse cortex following electroporation and exhibit
the same secreted pattern with dotty staining (Supplementary
Fig. 7a–h’). Also, the distribution of GFP+ electroporated cells
was indistinguishable between control, LGALS3BP, E370K, and
E294K (Supplementary Fig. 7i). However, both E370K and E294K
did not fully recapitulate the phenotype observed upon wt
LGALS3BP overexpression, namely the generation of ectopic
Hopx+ cells (Fig. 7a–e and Supplementary Fig. 7j). This suggests
that, in contrast to the forced expression of the wt form of
LGALS3BP, the variants are functionally insufficient to signifi-
cantly affect NPC misposition in mice where, under normal
conditions, aRGs are not generating increased number of BPs. In
addition, only a small proportion of the mice electroporated with
the two variants show the generation of folds (33% in E370K and
14% in E294K compared to 80% expressing wt LGALS3BP)
(Fig. 7f–n). Since LGALS3BP regulates apical anchoring during
COs development, we mechanistically investigated whether it acts
similarly in vivo in RGs. Thus, immunostaining for β-catenin was
performed after LGALS3BP overexpression in mice at 3dpe
(Fig. 7o–r). At the site of electroporation, but not in adjacent
regions or control electroporation, apical β-catenin was reduced
(arrowheads) at almost 75% of the section analyzed (Fig. 7w). On
the contrary, overexpression of the two LGALS3BP de novo
variants, E370K and E294K, could not recapitulate this phenotype
at full (Fig. 7s–w). Why the mutant LGALS3BP variants cannot
recapitulate the phenotype observed when the wt form is
introduced in the developing cortex of mouse can be attributed
to the fact that, under physiological conditions, LGALS3BP is not
expressed in the mouse. Thus, the overexpression of a less
functional variant of the gene does not change the physiological
expression levels which in turn explains the loss of the phenotype.
Overall, the above data suggest that forced expression of the
human version of LGALS3BP in a context where it is normally
not expressed, influences the anchoring of NPCs to the apical
side, thus their position in the developing cortex and the
generation of an oSVZ-like territory. Eventually, it regulates
neuronal output and expansion during corticogenesis, including
local gyrification in mice, which can adopt properties ascribed to
the human context. On the contrary, the genetic variations in the
Fig. 4 Proteomics, secretomics, and scRNA sequencing reveal altered signatures of the mutant cells in COs and cell non-autonomous effect of
LGALS3BP function. a, c Volcano plots illustrating the fold change of protein expression in the whole proteome (a) and in secretome (c) analysis in control
or mutant COs at 60d. b, d GO Term analysis on the differentially regulated protein in the proteome (b) or secretome (d) of control or mutant COs plotted
with reverse FDR and their fold enrichment. Data revealed higher enrichment of proteins with functions that are highly relevant to cortical development
such as neurogenesis, cell-substrate adhesion, extracellular matrix organization, and secretions via vesicles like exosomes. e UMAP embedding of 10X
genomics-based scRNA-seq data generated for 2 CTRL (9290 single cells), 2 Y366Lfs (5199 single cells), and 2 E370K (4095 single cells) COs prior to
data integration (left) and SPRING embedding of the data upon RSS integration (right). f Cell type annotation of organoid scRNA-seq data visualized in
the integrated SPRING embedding (see panel e). Three major progenitor-to-neuron trajectories can be seen for the dorsal telencephalon (shades of red),
the ventral telencephalon (shades of blue), and non-telencephalic cells (shades of green). g Heatmap showing the expression of genes used to define the
different cell types found in COs. The sidebar on the left denotes the cell states along the three main developmental trajectories (dorsal telencephalon, red;
ventral telencephalon, blue; non-telencephalic cells, green). h Barplots summarizing the relative proportion of cells for each of the three conditions (left), as
well as the total number of cells (right) detected for each cell state. i GO Term analysis on the differentially regulated genes in the RG population as where
identified form scRNA-seq analysis form control and mutant COs plotted with reverse FDR and their fold enrichment. Data revealed higher enrichment of
genes with cellular functions involved in extracellular exosomes, extracellular organelle and extracellular vesicles. See also Supplementary Fig. 4.
Abbreviations: CTRL: control, GO: gene ontology, FDR: false discovery rate, RG: radial glial cells, bRG: basal radial glial cells, IP: intermediate progenitor,
Telen.: telencephalon, Non-telen.: non-telencephalic, Expr.: expression.
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LGALS3BP gene, which possibly act as dominant-negative, fail to
promote the positioning of the NPCs in basal locations and
eventually proper cortical expansion in a context where the
endogenous Lgals3BP is not detectable.
LGALS3BP is secreted via vesicles mediating function in mice.
Our data suggest that LGALS3BP, a secreted protein that was
found in vesicles in the size of exosomes, changes the extracellular
environment during human cortical development modulating its
proper formation. In addition, scRNA-seq, proteomic and
secretomic analyses pinpointed the role of extracellular exosomes
in RGs as one of the most dysregulated processes. Finally, further
analysis in the DEGs from scRNA-seq of control and mutant CO
cells, showed that some of the transmembrane proteins char-
acterizing exosomes, such as CD81, CD82, and CD24 are dif-
ferentially regulated in the RG population (Fig. 8a and
Supplementary Data 1). Thus, we sought to investigate the role of
EVs in cortical development ex vivo.
We were able to detect LGALS3BP in EVs isolated from
control COs (Fig. 8b). To demonstrate that the function of
LGALS3BP in influencing the position of NPCs and neurons is
mediated by its content in secreted vesicles, we first produced EVs
overexpressing either HA alone or in frame with wt LGALS3BP
(HA-LGALS3BP), or the two genetic variants of LGALS3BP







































Fig. 5 Proper protein secretion mediates LGALS3BP function. a Scheme showing the experimental procedure of the switch medium experiment in COs.
b, c, e, f, h, i Micrographs of sections of E370K or Y366Lfs COs treated with control condition medium and immunostained as depicted in the panels.
d, g Quantification of the percentage of organoids with apically dividing PH3+ cells (d) or the phalloidin thickness of COs upon incubation of control,
E370K, or Y366Lfs mutant COs with CTRL, E370K, or Y366Lfs medium as indicated in the panels. Data are shown as Z-scores ±SEM, statistical
significance was based on two-tailed Mann-Whitney U test *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, batches= 1, organoids= 9, ventricles= 16.
In (d), p= 0.0026 in ctrlvsY366Lfs, p= 0.0357 in ctrlvsE370K+ctrlmedium, p= 0.0002 in Y366LfsvsY366Lfs+ctrlmedium. In (g), p= 0.0010 in
ctrlvsY366Lfs, p= 0.0384 in ctrlvsE370K+ctrlmedium. j Quantification of the percentage of organoids with ectopic neurons upon incubation of control,
E370K, or Y366Lfs mutant COs with CTRL, E370K, or Y366Lfs medium as indicated in the panels. Data are shown in percentages, statistical significance
was based on one-tailed exact binomial test *p < 0.05, **p < 0.01, ***p < 0.001, batches= 1, organoids= 9, ventricles= 16. In (j), p= 0.0376 in
ctrlvsE370K, p= 0.0002 in ctrlvsY366Lfs, p= 0.0012 in E370KvsE370K+ctrlmed, p= 0.0010 in Y366LfsvsY366Lfs+ctrlmed. Scale bar: 30 μm. See also
Supplementary Fig. 5. Abbreviations: CTRL: control.
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respectively) by overexpressing the constructs in SH-SY5Y cells
and isolating the EVs from their culture medium. Since
LGALS3BP has been found in circulating exosomes40, we first
tested that the EVs produced have a size between 100 and
150 nm, the typical size of exosomes (Supplementary Fig. 8a), and
that all the different LGALS3BP variants are present in EVs
(Fig. 8b). Then, we treated organotypic mouse slices isolated from
E13 mouse brains with the 4 collections of purified EVs. Control
organotypic slices without EV treatment were also analyzed in
parallel. Three days after the treatment, the mouse slices were
fixed and the number of basally located Hopx+ progenitors and
the position of Satb2+ neurons was assessed (Fig. 8c–g’, i–m’).
Mouse slices treated with HA-containing EVs did not differ from
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Interestingly, slices treated with EVs containing HA-LGALS3BP,
but not those treated with EVs containing the HA-E370K or HA-
E294K variants, showed significantly increased number of basal
Hopx+ cells (Fig. 8h), recapitulating the specific phenotype
observed upon overexpression of the different LGALS3BP
variants by in utero electroporation. In addition, mouse slices
treated with variants of LGALS3BP showed the different location
of neuronal clusters, observed ectopically in more apical
locations, compared to control conditions (Fig. 8n) reminiscing
the PH phenotype observed in patients.
Taken together, these results suggest LGALS3BP as a key
protein in RGs’ delamination and function, and in the regulation
of human neurogenesis, cortical expansion, and the appearance of
cortical gyrification. We propose that LGALS3BP is mostly
produced by NPCs early during human neurogenesis, it is
secreted via EVs and modulates the extracellular environment
leading to the loosening of the apical anchoring and delamination
of NPCs. Finally, this cascade of events may be responsible for the
correct positioning of some neurons (Fig. 8o and Supplementary
Fig. 8b).
Discussion
The evolutionary expansion of the human cerebral cortex in
comparison to that of other mammals occurred in concert with
the emergence of marked differences in the cognitive abilities of
our species. This expansion principally reflective of an increase in
the total number of neurons in the cortex was previously pro-
posed to be a consequence of an increased number of NPCs
during early developmental stages53,54. Thus, genes regulating the
pool of NPCs were considered important for determining human
brain size. Another key step in the expansion of the brain was the
emergence of a recently identified NPC type found in gyr-
encephalic species, the bRGs, and the expansion of the SVZ
including IPs, except bRGs. Despite the essential role of BPs in
human brain development, the mechanisms involved in their
generation and function are still poorly understood. Here, we
describe the role of LGALS3BP, a secreted protein that is part of
the extracellular environment and interacts with several ECM
proteins. LGALS3BP was depicted initially as one of the few genes
defining the molecular identity of human bRGs33, with compar-
ably low levels of expression in the mouse cortex18,24,32. By
performing a thorough expression analysis of LGALS3BP, we
show that its expression is enriched in gyrencephalic
species17,34,35,37, it characterizes the major human NPC popula-
tions, namely aRGs, bRGs, IPs, its expression arises after aRG
markers but before BP markers and interestingly, it is secreted.
These data suggest that LGALS3BP may be one of the earliest
genes regulating apical to basal NPC specification, placing it as a
key player in the evolution of the human cerebral cortex. A few
other genes have recently been described as key players: the
primate-specific isoform of PLEKHG6, which regulates the
number of apical versus basal NPCs11, the NOTCH2NL para-
logues which are a newly identified hominid-specific group of
duplicated genes shown to promote the expansion of cortical
progenitors in humans19, ARHGAP11B, a human-specific dupli-
cated gene, HOPX a bRG-specific gene promoting NPCs ampli-
fication and bRG generation in mice18,21,33,55, TMEM14B a
primate-specific gene promoting cortical expansion and folding
by marking bRGs56, and Trnp1 a gene highly expressed in mice
and which must be downregulated to regulate cerebral cortex
expansion in gyrencephalic species15. Our work, together with
previous studies, suggests that genes which are either human-
specific or have a human-enriched expression pattern are essen-
tial for the evolution of gyrified species and the human cortex
during development. Their importance is evident even in mice, a
model system that lacks folds under normal conditions, sug-
gesting that their expression should have been essential for the
evolution of folds. It is therefore important to identify those
human-specific or differentially expressed genes and to under-
stand how cortical gyrification occurs.
Our findings show that LGALS3BP expression is important for
the generation and positioning of apical and basal NPCs and
neurons in humans, human-specific models, and mice. Since an
important step during human neurogenesis is the migration of
neuronal cells towards the developing cortex, aberrant neuronal
migration can lead to ectopic neurons, resulting in cortical mal-
formations, such as PH. A key cellular mechanism essential for
correct neuronal migration is the morphology of aRGs. IPs and
bRGs were recently proposed to be involved in malformations
such as PH9,11,57–59. Individuals with genetic variations in
LGALS3BP can exhibit not only PH but also changes in cortical
thickness and the LGI. Thus, we propose that BPs’ delamination
mediated by LGALS3BP is critical for proper neuronal position-
ing and gyrification in humans. Furthermore, many cortical
malformations are known to cause developmental delay and
cognitive impairment60. Higher cortical functions, underlying
cognitive processes, are one of the hallmarks of human evolution,
suggesting that potential mechanisms regulating cortical evolu-
tion may interplay or be disrupted when cortical malformations
occur. Therefore, candidate genes involved in both processes are
of great importance. Interestingly, two other de novo mutations
in LGALS3BP were identified in a cohort of individuals with
autism spectrum disorder and a cohort with schizophrenia61,62,
and together with the fact that LGALS3BP is found in the recently
developed SZDB database63 and it is detected in the serum pro-
teomes of patients with schizophrenia it suggests its potential
contribution to the development of such disorders64. Moreover,
the missense variant found in individual 1, exhibiting PH and GI
abnormalities, is among the small number of non-conserved
residues between human and macaque LGALS3BP65. Most of the
non-conserved residues in macaque and the LGALS3BP human
variants identified here are in exon 5, which is the region of the
gene most intolerant to the acquisition of variation in healthy
humans. Moreover, the expression of LGALS3BP in macaque-
derived organoids shows a much lower number of cells expressing
LGALS3BP compared to human-derived organoids37. These
Fig. 6 Overexpression of LGALS3BP in mouse brain results in changes in the progenitors’ position and folded cortex. a–d, f–i, k–n Micrographs
of sections of mice immunostained as depicted in the panels after electroporation of control or LGALS3BP at embryonic day 13 and analyzed 3dpe.
e, j, o Quantification of the distribution of the Pax6+, Hopx+ or Tbr2+ cells in the developing cortex. Data are shown mean ± SEM. Statistical significance
was based on two-tailed Mann-Whitney U test *p < 0.05, **p < 0.01, n= 4 independently processed animals. In (e), p= 0.0286 in ctrlvsLGALS3BP in BinA,
p= 0.0286 in ctrlvsLGALS3BP in BinC. In (j), p= 0.0031 in ctrlvsLGALS3BP in BinA, p= 0.0159 in ctrlvsLGALS3BP in BinC. In (o), p= 0.0286 in
ctrlvsLGALS3BP in BinC. p–w Micrographs of sections of mice immunostained as depicted in the panels after electroporation of control or LGALS3BP at
embryonic day 13 and analyzed 6dpe. LGALS3BP overexpression resulted in the formation of fold-like structures, which include deep (Tbr1) and upper
(Satb2) layer neurons. x Quantification of the percentage of animals that had no folds (white), minor folds (black) or major folds (gray). Statistical
significance was based on one-tailed exact binomial test **p < 0.01 ****p < 0.0001. Scale bar: 30 μm in (a–d, f–i, k–n), 200 μm in (p–w). See also
Supplementary Fig. 6. Abbreviations: CTRL: control, dpe: days post electroporation.
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observations could suggest that this is a region of the gene which
is of great importance for the acquisition of human-specific
functions associated with gyrification.
Our data strongly indicate that the position of NPCs and
neurons during human neurogenesis is mediated by the regula-
tion of the extracellular niche where human NPCs are found,
which modulates the proper anchoring of the apical progenitors
to the VZ. We speculate that changes in the niche regulate the
position of NPCs, and consequently the neuronal output during
human cortical development. Here, we aim to bridge these
mechanisms with the involvement of mechanical forces, which
were recently suggested to be important for the proper folding of
the human cortex23. Precedent exists for the importance of
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involved in intercellular adhesion, as well as ECM components,
such as HAPLN1, lumican, and collagen I, are examples of genes
that have already been implicated in the development of the
human cortex and gyrification25,36. In addition, members of the
collagen family have been implicated in human cortical devel-
opment and malformations43,66. In parallel to these, we show that
LGALS3BP, another ECM-interacting protein, can also lead to
defects in gyrification in individuals with LGALS3BP variants.
More importantly, our work proposes that ECM, with LGALS3BP
as a potential mediator of the ECM cues, can influence human
cortical development at the cellular level. Interestingly, the
crosstalk between ECM, LGALS3BP, and tetraspanins, which was
proposed to regulate cell migration in cancer31,67, could influence
the rearrangement of the cytoskeleton and adhesion. Similarly, we
show that LGALS3BP regulates the apical anchoring of NPCs in
the VZ by influencing the function of apical polarity proteins and
thus modulating BPs delamination. We also show that mutations
in LGALS3BP change the composition of secreted proteins, and
that it is present in EVs and that treatment with EVs expressing
LGALS3BP is sufficient to reproduce the phenotype observed
upon manipulation of its expression in vivo. We also point out
that ECM components and exosomal receptors, such as tetra-
spanins with unique evolution-dependent expression patterns
and/or specific abundance in the niche of human NPCs, are
regulated by correct LGALS3BP expression and secretion.
Mechanistically, we propose that the extracellular environment is
affected by modulations of the expression of such proteins, cap-
able of dynamically modifying the extracellular niche and
resulting in loosening of the apical belt, delamination of BPs, and
eventually changes in the neuronal output and cortical folding.
Whether the changes in the niche of humans, when LGALS3BP
genetic variations occur, are the consequence or the cause of their
detachment/non-detachment from the apical belt is still uncer-
tain. However, we favor the hypothesis that the niche influences
the apical anchoring, this in turn influences NPC identity and fate
as delaminated cells have their cell bodies in a different position
and are exposed to different environmental cues.
Together, we suggest that LGALS3BP modulates the extra-
cellular environment, regulates BPs delamination and thus,
proper cortical formation and gyrification, as well as represent
evidence that dysregulation of BPs position, morphology, and
molecular identity can mechanistically underpin cortical
malformations.
Methods
iPSC culture. Induced pluripotent stem cells (iPSCs) reprogrammed from NuFF3-
RQ human newborn foreskin feeder fibroblasts (GSC-3404, GlobalStem)68. Sub-
jects gave consent for the generation of iPS cells (ISFi001-A). MTA approval for the
use of this line of iPSCs was acquired. iPSCs were cultured on Matrigel (Corning)
coated plates (Thermo Fisher, Waltham, MA, USA) in mTesR1 basic medium
supplemented with 1x mTesR1 supplement (STEMCELL Technologies, Vancouver,
Canada) at 37 °C, 5% CO2, and ambient oxygen level. Passaging was done by
Accutase (STEMCELL Technologies) treatment.
CRISPR genome editing for generation of mutant iPSCs lines. For CRISPR
genome editing for the generation of mutant COs, one control iPSC line was used
to generate isogenic control and mutant lines. CrRNA was selected based on
Geneious Prime, CCtop69 and a guide design tool by Zhang lab (CRISPR.MI-
T.EDU). The selected CrRNA (5′ AGTTCAACCTGTCCCTGTAC 3′) was
assembled and in vitro transcribed into guideRNA (gRNA) by EnGen sgRNA
Synthesis Kit, Streptococcus pyogenes (E3322S, NEB). The in vitro-transcribed
guide was assembled into a gRNA-CAS9-NLS RNP complex by incubating the
CAS9-NLS (M0646M, NEB) and in vitro-transcribed gRNA for 20 min at RT
followed by electroporation into single cells of iPSC line using Amaxa 4D
Nucleofector (Lonza). For generating the variation found in individual 1 (E370K)
or the truncated/knockout exon5 line (Y366Lfs), targeting oligo (139 bp) was added
into the gRNA-CAS9-NLS RNP tube prior to electroporation. Electroporated cells
were plated onto a 10 cm Geltrex (A1413302, Thermo Fischer Scientific) coated
dish supplemented with mTesR1 (85850, STEMCELL Technologies) and Y-27632
(72308, STEMCELL Technologies). The electroporated cells were allowed to
recover for 10d with daily media changes of mTeSR1 before single-cell live sorting
into Geltrex-coated 96-well plates using CloneR (05888, STEMCELL Technolo-
gies). The iPSC colonies were screened using the protocol by Yusa K70 with the
primers as listed in Supplementary Data 5.
The resulting PCR product (644 bp) was cloned and Sanger sequenced using the
NEB PCR Cloning Kit (E1202S, NEB) to screen the individual genomic alleles.
The manufacturer’s recommendations/kit protocols were followed for all the
kits/reagents mentioned above.
Sequencing the genomic regions after targeting and for OFF targets. Genomic DNA
was isolated from the E370K and Y366Lfs iPSC lines using QIAamp DNA Mini Kit
(51306, QIAGEN) using the manufacturer’s recommendations. The purified
genomic DNA was used as a template to amplify the individual targeted and the
putative off-target genomic loci predicted by the aforementioned guide design
online tools and software. All the Sanger sequencing was performed at the
Sequencing Facility of the Max Planck Institute of Molecular Cell Biology and
Genetics, Dresden, Germany.
The information regarding the CrRNA, the targeting oligo, and the top 4 exonic
positions of the putative off-targets, primer sequences, and amplified product sizes
that were sequenced in the knockout (KO), and the patient-specific iPSC lines are
included in Supplementary Data 4.
Constructs for LGALS3BP manipulation
Generation of overexpression constructs for LGALS3BP. To overexpress in COs and
in mice, the LGALS3BP gene, the open reading frame of the human LGALS3BP
gene, was cloned into the PCAGGS plasmid vector71 using standard cloning
methods. To overexpress LGALS3BP in SH-SY5Y cells, the open reading frame of
human LGALS3BP was cloned into the HA pcDNA3.1 plasmid vector (genescript)
in frame with HA. For overexpression of the two variants found in the individuals
with cortical malformations, the LGALS3BP in the PCAGGS or the pcDNA3.1
plasmid vectors were used as a template for point mutagenesis using the Q5® Site-
Directed Mutagenesis Kit (BioLabs). The primers used for this procedure are listed
in Supplementary Data 5.
As control and overexpression, the empty PCAGGS or HA pcDNA3.1 plasmid
vectors were used, respectively.
Generation and analysis of COs. COs were generated as previously described38.
Briefly, iPSCs were dissociated into single cells using StemPro Accutase Cell Dis-
sociation Reagent (A1110501, Life Technologies) and plated in the concentration of
Fig. 7 Overexpression of the LGALS3BP variants in the mouse brain only partially recapitulates the phenotype. a–d Micrographs of sections of mice
immunostained for Hopx after electroporation of the E370K or the E294K variants of LGALS3BP at embryonic day 13 and analyzed 3dpe. e Quantification of
the distribution of the Hopx+ cells in the developing cortex. Data are shown as mean ± SEM. Statistical significance was based on the two-tailed Mann-
Whitney U test *p < 0.05, n= 5 ctrl, 4 LGALS3BP, 3 E370K, 4 E294K independently processed animals. In (e), p= 0.0317 in ctrlvsLGALS3BP in BinA,
p= 0.0286 in LGALS3BPvsE394K in BinA, p= 0.0159 in ctrlvsLGALS3BP in BinC, p= 0.0286 in LGALS3BPvsE394K in BinC. f–m Micrographs of sections
of mice immunostained as depicted in the panels after electroporation of the E370K or the E294K variants of LGALS3BP at embryonic day 13 and analyzed
6dpe. Overexpression of the LGALS3BP variants cannot fully recapitulate the formation of fold-like structures, which the wt form of LGALS3BP generates.
n Quantification of the percentage of animals that had no folds (white), minor folds (black) or major folds (gray). o–v Micrographs of sections of mice
immunostained as indicated in the panels after electroporation of control (o, p), LGALS3BP (q, r), or the two LGAS3BP variants (s–v) at embryonic day 13
and analyzed 3dpe. Green arrows depict the electroporated area and red arrows the adjacent area. w Quantification of the percentage of mice with intact or
patchy apical junction upon overexpression of the different forms of LGALS3BP. Statistical significance was based on the one-tailed exact binomial test,
*p < 0.05, ***p < 0.001. In (n), p= 0.0170 in LGALS3BPvsE370K, p= 0.0004 in LGALS3BPvsE294K. In (w), p= 0.0039 in LGALS3BPvsE370K, p= 0.0039
in LGALS3BPvsE294K. Scale bar: 30 μm in (a–d), 200 μm in (h–m, o–u’). See also Supplementary Fig. 7. Abbreviations: CTRL: control, dpe: days post
electroporation, LFQ: labeled free quantification.
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9000 single iPSCs/well into low-attachment 96-well tissue culture plates in hES
medium (DMEM/F12GlutaMAX supplemented with 20% Knockout Serum
Replacement, 3% ES-grade FBS, 1% nonessential amino acids, 0.1 mM 2-mercap-
toethanol, 4 ng/mL bFGF, and 50 µM Rock inhibitor Y27632) for 6d in order to
form embryoid bodies (EBs). Rock inhibitor Y27632 and bFGF were removed on
the 4th day. On day 6, EBs were transferred into low-attachment 24-well plates in
NIM medium (DMEM/F12GlutaMAX supplemented with 1:100 N2 supplement,
1% nonessential amino acids and 5 µg/mL Heparin) and cultured for additional 6d.
On day 12, EBs were embedded in Matrigel (Corning, 354234) drops and then they
were transferred in 10 cm tissue culture plates in NDM minus A medium (DMEM/
F12GlutaMAX and Neurobasal in ratio 1:1 supplemented with 1:100
N2 supplement 1:100 B27 without vitamin A, 0.5% nonessential amino acids,
insulin 2.5 µg/mL, 1:100 Antibiotic-Antimycotic, and 50 µM 2-mercaptoethanol) in
order to form COs. At 4d after Matrigel embedding, COs were transferred into an
orbital shaker and cultured until electroporation in NDM plus A medium (DMEM/
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N2 supplement 1:100 B27 with vitamin A, 0.5% nonessential amino acids, insulin
2.5 µg/mL, 1:100 antibiotic-antimycotic, and 50 µM 2-mercaptoethanol). During
the whole period of CO generation, cells were kept at 37 °C, 5% CO2, and ambient
oxygen level with medium changes every other day. After transferring the COs
onto the shaker, the medium was changed twice per week. COs were cultured up to
30, 40, 60, or 80d as indicated. For testing the effect of the secreted medium in COs
cultures, COs from the same batch were cultured without medium switch until 16d.
From 17 to 60d, the medium was switched every day by removing all the medium
from the COs and adding half fresh medium and half condition medium from
different genotype COs as described in the panels (Fig. 8 and Supplementary
Fig. 8). COs were fixed using 4% PFA for 1 h at 4 °C, cryopreserved with 30%
sucrose and stored at −20 °C. For immunofluorescence, 16 µm cryosections were
prepared. For each experiment, many independent ventricles per CO from at least
3 different COs generated in 2–3 independent batches were analyzed.
Generation of neural progenitor cells and neurons. NPCs were generated as
described previously72 with modifications. In short, EBs were generated from iPSCs
by plating colonies in suspension in the neural induction medium consisting of
DMEM F12 with N2 and B27 supplements (Thermo Fisher). EBs were plated on
polyornithine and laminin (Sigma Aldrich, St. Louis, MO, USA) coated dishes and
cultured for 7d in the neural induction medium. Neural rosettes were manually
picked using a stereological microscope (Nikon, Tokyo, Japan) and a P1000 tip,
manually dissociated and further cultivated in neural progenitor medium (neural
induction medium supplemented with bFGF at 20 ng/mL; Peprotech, Rocky Hill,
NJ, USA). For passaging, the cells were dissociated using Accutase (STEMCELL
Technologies) and split at a maximum ratio of 1:3.
Electroporation of COs. COs were kept in antibiotic-free conditions prior to
electroporation. Electroporation was performed in COs at around 40d stages after
the initial plating of the cells, and fixed 4dpe. During electroporation, COs were
placed in an electroporation chamber (Harvard Apparatus, Holliston, MA, USA)
under a stereoscope, and using a glass microcapillary of 1–2 µL, plasmid DNA was
injected together with Fast Green (0.1%, Sigma) into different ventricles of the COs.
COs were subsequently electroporated with 5 pulses applied at 80 V for 50 ms each,
at 500 ms intervals (ECM830, Harvard Apparatus). Following electroporation, COs
were kept for additional 24 h in antibiotics-free media and then changed into the
normal media until fixation. COs were fixed using 4% PFA for 1 h at 4 °C, cryo-
preserved with 30% sucrose and stored at −20 °C. For immunofluorescence, 16 µm
cryosections were prepared. For each experiment, many independent ventricles per
CO from at least 3 different COs generated in 3 independent batches were
analyzed.
In utero electroporation. Pregnant C57BL/6 mice were used as approved by
the Government of Upper Bavaria under license number 55.2-1-54-2532-79-2016
(we have complied with all relevant ethical regulations for the use of mice). Mice
were housed in case of a maximum of 3 animals per cage in a room with a 12-hour
light–dark cycle, room temperature (RT) 20–24 °C, and relative humidity 45–65%.
Mice were anesthetized by intraperitoneal injection of saline solution containing
fentanyl (0.05 mg per kg body weight), midazolam (5 mg per kg body weight), and
medetomidine (0.5 mg per kg body weight) (Btm license number 4518395), and
E13 embryos were electroporated as described73. In brief, plasmids were mixed
with Fast Green (2.5 mg/μL; Sigma) and injected at a concentration of 1 μg/μL.
Anesthesia was terminated by injection of buprenorphine (0.1 mg per kg body
weight), atipamezole (2.5 mg per kg body weight), and flumazenil (0.5 mg per kg
body weight). Brains were fixed at 3dpe, 6dpe, or 13dpe in 4% PFA overnight. For
immunofluorescence, 12 µm cryosections were prepared. For each experiment, at
least 3 different mouse brains were analyzed.
Human samples. During the autopsy, human embryonic tissues at GW14–18
containing prefrontal cortex from one hemisphere were collected, stored on ice in
DMEMF12 media and transported to the lab (ABM approval: PFS17-003) (we have
complied with all relevant ethical regulations for the use of human embryonic
tissues). Samples were then divided into smaller pieces and included in 4% low-
gelling agarose with artificial cerebrospinal fluid74. DNA was injected through the
gel, at the ventricular surface. A series of five electric pulses at 50 V for 50 ms at 1 s
intervals were applied to the gel block. Tissue was then sliced at 300 µm and placed
on Millicell-CM inserts (Millipore) in a cortical culture medium. After 6d of cul-
ture, tissues were fixed for 1 h in 4% PFA, detached from the insert, and stored at
4 °C in PBS. Brain slices were incubated in blocking solution (1X PBS, 0.3% Triton
X-100, 2% normal donkey serum) for 2 h without agitation at RT. Slices were then
incubated with primary antibody diluted in blocking solution overnight at 4 °C,
washed, and incubated with secondary antibody diluted in blocking solution
(Jackson ImmunoResearch) overnight at 4 °C. Incubation with 1X DAPI was
included with the secondary antibody to visualize nuclei. Slices were washed for 1d
before mounting.
We utilized whole-exome sequence data 65 trios (affected child and both
parents) characterized and contributed by us in a previous study11. These
individuals are also described in an additional study43 where participants can be
identified through the prefix ‘pvhnz’ in the cohort identifier table. In this same
table, the sex of these participants can also be identified. All study participants were
ascertained by physician referral, and phenotypes were assessed as sporadic based
on patient and family interviews. The first patient was consented to participate
under the University of Otago consent protocol. Parents or legally authorized
representatives gave signed consent to participate in this study under protocols that
were approved from either the Southern Regional Ethics Committee O03/016 or
the New Zealand Ethics Committee MEC08/08/094 and was conducted in
accordance to the criteria set by the Declaration of Helsinki. For the New Zealand-
based study, general sharing of individual exome sequences was not approved on
confidentiality grounds. The second patient, of whom clinical data were obtained,
was identified within the DDD study44. This study has UK Research Ethics
Committee approval (10/H0305/83), granted by the Cambridge South Research
Ethics Committee and was conducted in accordance with the criteria set by the
Declaration of Helsinki. All patients or their guardians provided written informed
consent.
Morphometric analysis on individual MRIs. T1-weighted MRI of the individual
was processed according to a surface-based approach46, to assess cortical thickness
(CT)75, LGI47, surface area (SA)76, and sulcal depth in different gyral and sulcal
regions of the cortex77. Statistical analysis of morphometric data was performed
comparing the individual with a template obtained by averaging 8 age-matched
controls (ages: 15.6 ± 2.2 years, for subject 1; 1.1 ± 0.2 years, for subject 2). In order
to detect differences in morphometric features for each hemisphere, the compar-
ison was performed by a two-tailed paired t-test and cortical maps were clustered
and corrected for multiple comparisons using a Monte-Carlo simulation (1000
iterations, Z-value= 1.3, cluster-wise p-value < 0.05). Cluster analysis in individual
1 (Fig. 2a) revealed reduced cortical thickness in the pre- and para-central gyri in
both hemispheres. Clusters of increased LGI were found in the left lateral occipital
gyrus and the anterior caudal segment of the right cingulate gyrus. LGI maps also
disclosed simplified sulcal patterns, with reduced LGI, in the left superior-frontal
and in the right medial orbitofrontal gyri. A statistically significant increase in the
surface area was found bilaterally in rostral middle frontal and supramarginal gyri,
in the right inferior-temporal gyrus, in the left insula, and in the precuneus. An
increased sulcal depth was observed in the anterior part of the superior-temporal
gyrus. Cluster analysis in individual 2 (Fig. 2a’) revealed statistically significant
diffuse abnormalities in the cortex, with increased thickness in cortical areas
located between the precentral and the superior-frontal gyri in both hemispheres.
Calculation of the LGI maps disclosed simplified sulcal patterns. Clusters of
reduced LGI were found in the precentral, postcentral, and supramarginal gyri in
both hemispheres. The area of the cortical surface appeared reduced in the left
precuneus and the vertex of the postcentral gyrus. No alterations of the sulcal depth
were found. Collectively, both individuals show morphometric changes in multiple
cortical areas (Fig. 2a, a’).
Fig. 8 LGALS3BP function is mediated by EVs. a Violin plots showing the distribution of gene expression, which are up- or downregulated in mutant cells
in scRNA-seq analysis. b Western blot analysis for the expression levels of HA, LGALS3BP, or CD81 antibodies performed in protein extracts isolated from
EVs derived from control COs or SH-SY5Y cells upon electroporation of HA, HA-LGALS3BP, HA-E370K, or HA-E294K batches= 2, organoids= 6, cell
batches= 3. Source data are provided as a Source Data file. c–m’ Immunostaining as indicated in the panels of non-treated control mice sections
or after incubation with SH-SY5Y-derived EVs overexpressing HA, HA-LGALS3BP, HA-E370K, or HA-E294K at embryonic day 13 and analyzed 3dpe.
h, n Quantification of the percentage of basal Hopx+ cells (h) or the distance from the ventricular surface where the first neuronal positive cells are found
(n) after treatment of control mouse sections with EVs overexpressing HA, HA-LGALS3BP, HA-E370K, or HA-E294K. Data are shown as Z-scores ±SEM.
Statistical significance was based on one-way ANOVA and Turkey’s multiple comparison test *p < 0.05, **p < 0.01, ***p < 0.001, n= 3 mice in no EVs, HA
EVs, wt-LGALS3BP EVs, n= 4 mice in E370K EVs, n= 5 mice in E294K EVs. In (h), p= 0.0002. In (n), p= 0.0142. Scale bar: 200 μm. o Summary scheme
showing that LGALS3BP is secreted via EVs protein, which upon secretion modulates the extracellular space and promotes changes in the distribution of
the apical and basal progenitor cells which in turn regulates proper cortical development. Abbreviations: CTRL: control, MUT: mutant, UMI: Unique
molecular identifiers, MAX: maximum, kDa: kilo Dalton, Lad: ladder, dpe: days post electroporation, EVs: extracellular vesicles.
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Electroporation in SH-SY5Y cells, EVs isolation, and treatment in organotypic
mouse sections. SH-SY5Y cells were cultured in DMEM/F12GlutaMAX medium
supplemented with 10% FBS and 1% antibiotics at 37 °C, 5% CO2, and ambient
oxygen level. Passaging was done using trypsin/EDTA (Sigma) treatment. For the
production of extracellular vesicles, 1d before the start of the experiment (day −1)
cells were cultured in media with FBS depleted from bovine exosomes (FBS was
ultracentrifuged in 100,000g for 2 h and the supernatant was collected and used on
the cells). On day 0, 2 million cells (80% confluency) were cultured in 15 cm plates
in DMEM/F12GlutaMAX medium supplemented with 10% FBS (exosomes
depleted) without antibiotics, and overexpression of HA, HA-LGALS3BP, HA-
E370K, or HA-E294K, was performed via electroporation with 4 μgr of pcDNA3.1
expression construct using the Amaxa Nucleofector at the program G004. The
following day (day 1), antibiotics were added to the medium. On day 2, the
medium of the electroporated cells was collected and processed in a series of
centrifugations (medium centrifugation in 300g for 15 min, supernatant cen-
trifugation in 2000g for 10 min, supernatant centrifugation in 10,000g for 30 min,
supernatant centrifugation in 100,000g for 120 min, and pellet wash with 1x PBS
and centrifugation in 100,000g for 60 min) to enrich for extracellular vesicles. For
the nanoparticle tracking analysis (NTA), extracellular vesicle suspensions were
diluted in PBS and analyzed using a Particle Metrix ZetaView® (Particle Metrix
GmbH, Inning am Ammersee, Germany) equipped with a 520 nm laser. The
manufacturer’s default software settings for EVs were selected accordingly. For
each measurement, samples were introduced manually and two cycles were per-
formed by scanning at 11 discrete positions in the cell channel and capturing 60
frames per position (video setting: high). After capture, the videos were analyzed
for particle size and concentration using the ZetaView Software 8.05.12 SP1. This
analysis showed that 2 million cells produced 6,700000e+ 008 particles per mL in
control condition (HA), 6,100000e+ 008 particles per mL in HA-LGALS3BP,
7,400000e+ 008 particles per mL in HA-E370K, and 3,500000e+ 008 particles per
mL in HA-E294K. In all the conditions, the particle size was approximately around
150 nm. For the in vivo treatment of EVs on organotypic mouse slides, at the final
step of EVs isolation the pellets were resuspended in 500 µL of mouse slice medium
[DMEM/F12 (powder; Sigma; D2906), 2% Horse Serum (Gibco), 2% FCS (Gibco),
0.8% B27 (Gibco; 17504-044), 4% N2 (Gibco; 17502-048), and 1% P/S(Gibco)]. In
parallel, control mouse brains from E13 mouse embryos were isolated, embedded
into 3% of low-melting agarose, and cut in vibratome at 300 µm thick sections. The
sections were placed on top of a cell culture insert (Millicell; PICMORG50) and
cultured for 3d with 500 µL of mouse slice medium and 500 µL of the EVs-
containing medium. After 3d, the sections were fixed with 4% PFA for 1 h and
processed for immunofluorescence.
Immunohistochemistry. Immunostainings on sections were performed as
described previously78. Briefly, sections were postfixed using 4% PFA for 10 min
and permeabilized with 0.3% Triton X-100 (1332481001, Sigma-Aldrich) for 5 min.
Sections were subsequently blocked with 0.1% TWEEN-20 (P9416, Sigma-Aldrich),
10% Normal Goat Serum, and 3% BSA. Immunostaining on floating sections was
performed as follows: sections were placed in 24-well plates and washed with 1X
PBS+ 0.1% TWEEN, and then permeabilized and blocked with blocking solution
containing 10% normal goat serum (NGS) (VEC-S-100 Biozol), 3% BSA, 0.3%
Triton X. Primary and secondary antibodies were diluted in blocking solution.
Nuclei were visualized using 0.5 µg/mL 4,6-diamidino-2-phenylindole (DAPI,
Sigma Aldrich). Immunostained sections were analyzed using Leica laser-scanning
microscope. F-ACTIN was visualized by incubation with Alexa Fluor 488-
conjugated PHALLOIDIN (Thermo Fisher) according to the manufacturer’s pro-
tocol. See the list of antibodies in Table 1.
In situ hybridization. Probes for in situ hybridization were generated as
described71. Linearized in situ plasmids were in vitro transcribed using DIG NTP
labeling mix, RNA polymerase T7 and T3, for sense and anti-sense probes,
respectively, as well as RNAse inhibitor (Roche). In situ mRNA transcript detection
was performed according to standard procedures.
FACS analysis. COs (30, 60, or 80d in culture) were collected for FACS analysis.
Three to six samples were analyzed; every sample contained 3 individual COs. COs
were enzymatically dissociated with Accutase, at 37 °C for 30 min. During incu-
bation, every 10 min the COs were triturated with a P1000 pipette. After dis-
sociation, samples were washed in PBS by centrifugation at 300g for 5 min. The cell
suspension was filtered through a 100 µm cell strainer and centrifuged at 300g for
5 min, and the cells were fixed in 70% ice-cold Ethanol. After 1 h at −20 °C,
samples were centrifuged for 30 min at 500g and then resuspended in 5 mL staining
solution (PBS containing 1% FCS). After further centrifugation for 30 min at 500g,
the cell pellet was resuspended in a staining solution containing anti-Pax6 antibody
(1:250, see Table 1), anti-HOPX antibody (1:250, see Table 1), or anti-DCX anti-
body (1:250, see Table 1) and incubated for 30 min at 4 °C. After washing in the
staining solution, cells were resuspended in a staining solution containing Alexa-
Fluor546 anti-guinea pig, AlexaFluor488 anti-rabbit (1:800), or AlexaFluor488
anti-mouse, secondary antibodies and incubated for 30 min at 4 °C. After washing
in PBS, cells were resuspended in PBS. FACS analysis was performed at a FACS
Aria (BD) in BD FACS Flow TM medium, with a nozzle diameter of 100 µm. For
each run, 10,000 cells were analyzed.
Gating strategy. SSC-A/FSC-A gates were done to exclude cell debris and FSC-W/
FSC-A to collect single cells (Source Data file). Specifically, the boundary between
positive- and negative-staining cells was set according to each isotype control.
Debris and aggregated cells were gated out by forward scatter and sideward scatter;
single cells were gated out by FSC-W/FSC-A. Gating for fluorophores was done
using samples stained with secondary antibody only. The flow rate was below 500
events/s.
Western blot. Cells or COs were lysed in lysis buffer (62.5 mM Tris-HCl, pH 6.8,
2% SDS, 10% sucrose in H2O) with protease and phosphatase inhibitors (Roche,
Basel, Switzerland) and approximately 20 µg of protein extracts were separated by
SDS-PAGE with a 10% gel. Proteins were transferred to a nitrocellulose membrane
(GE Healthcare, Chalfont St Giles, Buckinghamshire, Great Britain). For detection,
membranes were incubated with primary antibodies overnight and with horse-
radish peroxidase-labeled secondary antibodies at RT for 1 h, and afterward treated
with ECL Western Blotting Detection Solution (Millipore, Billerica, MA, USA) to
visualize bands. Bands were processed using Image Lab software.
Antibodies. See Table 1 for the list of antibodies used.
Cell and tissue quantifications. For the analysis of the electroporated COs and
mice, the positive cells as indicated on the panels were quantified in at least 12
different CO ventricles from at least 6 COs generated in two independent pre-
parations, or at least 6 mouse cortical sections from at least 4 embryos collected
from 2 or more littermates. Analysis of the phenotype of the manipulation of
LGALS3BP expression upon electroporation in COs was performed by always
comparing COs grown in parallel in the same batch. Moreover, the findings were
reproduced in different batches of organoids, grown at different times. Specifically,
the analysis was performed as follows: only SOX2+ or HOPX+ cells found in the
neurogenic zones were quantified, the number NEUN+ cells was quantified
regardless if they reach the cortical plate or not. The number of puncta after
immunostaining with LGALS3BP-specific antibody was performed with the puncta
quantification plugin in ImageJ. For human fetal tissue, four samples ranging from
GW14 to 18 were analyzed and a total of 7081 electroporated cells were counted. In
the electroporation of these samples, the number of SOX2+ and NEUN+ cells
found exclusively in the oSVZ were counted. For statistics, experiments were
compared in a pared manner, to account for sample-to-sample variability. Analysis
in the developing mouse cortices after electroporation was always performed and
represented in the figures in the middle of the electroporation where the phenotype
was strongest and more representative. For the total number of Hopx+, Pax6+, or
Tbr2+ cells in the mouse cortex, pictures of the same size were used. For the
distribution of the GFP+, Hopx+, Pax6+, or Tbr2+ cells in the mouse cortex, the
cortex was subdivided into 5 equal bins—BinA corresponded to the apical side and
BinE to the pial side of the cortex—in at least 6 sections from at least 4 embryos
collected from 2 or more litters. To distinguish the degree of cortical folding in mice,
we classified the folds in 6 or 13dpe as major when more than two sulci and gyri
were observed, and as minor when only one gyrus was observed; while at 3dpe, mice
with minor folds were characterized based on bulges of the Ctip2 neuronal layer.
Analysis in the organotypic mouse slices after EVs incubation was always performed
as follows: the number of Hopx+ cells found in basal from the VZ locations was
quantified per cortex, the distance from the apical size of the cortex of the first
cluster of NeuN+ cells with more than 5 cells was quantified in five different
positions per cortex and normalized by the apical-to-pial surface length. In the
control and mutant COs, the analysis was performed as follows: The CO size was
measured by analyzing at least 12 COs from three independent preparations based
on the surface of the COs. For the quantification of proliferating apical and basal
NPCs, all PH3+ cells located either at the apical or at the basal side of the VZ were
quantified from at least 3 COs and in at least 12 different ventricles, and then the
cell counts were normalized by the length of the apical membrane side of the VZ.
The analysis of non-delaminating HOPX+ cells was done by quantifying the
number of ventricles which included more than 5 HOPX+ cells having an apical
process as shown in Fig. 4i”–k”. The analysis of the heterotopic NEUN+ cells in the
VZ of control and mutant COs with or without LGALS3BP electroporation was
performed by quantifying the number of ventricles, including more than 5 NEUN+
cells next to the ventricular lumen and at least 3 COs and at least 10 different
ventricles were used for this analysis. The FABP7+ cells were calculated by counting
the total number of FABP7+ nuclei found within the neurogenic zones of the COs.
The apical belt thickness was identified using phalloidin, Pals1, or pan-cadherin
immunostaining measuring at five different positions per germinal zone along the
belt and normalizing the data by the length of the apical side of the VZ. The
integrity of the apical junction was assessed by the continuous or patchy line of β-
catenin or phalloidin staining in areas where the apical belt was well defined
(ventricle form control of mutant organoids which did show properly defined
staining of the apical anchoring markers at least in the dorsal part of the ventricles
and in apical positions from the VZ were excluded from the analysis). All analyses
were performed using ImageJ, Image Lab, Photoshop, or Illustrator and the
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appropriate statistical software package GraphPad for each analysis test as indicated
in the figure legends. Nonparametric tests were chosen since they are more strin-
gent. Details for the number of repetitions for each experiment are also included in
the figure legends. Unless mentioned otherwise, measurements were taken from
distinct samples. In graphs that are represented as Z-scores, Z-scores were generated
from the raw data using the STANDARDIZE formula from the excel function
where the ctrl mean and standard deviation were used.
Bulk RNA-seq experiments. COs (17, 23, 40, 70, 120, 140, or 158d in culture)
were collected for bulk RNA extractions using the RNeasy Mini extraction kit
(74104, QIAGEN) according to the manufacturer’s instructions. Three replicates
were analyzed per time point, with every sample containing 1–3 COs pooled.
Sequencing libraries were prepared using the NEBNext® Ultra™ DNA Library Prep
Kit for Illumina (E7370L, New England Biolabs) using ribosomal depletion as a
selection method, and sequenced paired-end on an Illumina HiSeq4000 system at
the Helmholtz Zentrum Core Facility (Munich, DE). Raw reads were processed
using FastQC and cutadapt79 and aligned using the STAR aligner80. The counts
data were batch-corrected, normalized, and analyzed using the ImpulseDE2
framework81.
Dissociation of COs for scRNA-seq. COs were dissociated as described in Mil-
tenyi’s Neural Tissue Dissociation protocol under sterile conditions. Samples were
selected at day 60 and processed enzymatically to get a single-cell suspension.
Firstly, each sample was cut into pieces and washed up to three times in 1x HBSS
without Ca2+ and Mg2+ (HBSS w/o). Then samples were incubated for 15 min at
37 °C in the Enzyme Mix 1 with Papain (2 mL) and Enzyme Mix 2 (30 μL) was
added once tissue started to disintegrate. In order to get sufficient dissociation,
samples were gently triturated using 1 mL pipette tip and incubated for another
15 min at 37 °C. To evaluate the dissociation progress, the cell suspension was
checked under the microscope. To generate single-cell suspension and remove
clumps of cells, samples were applied to 30 and 20 μm diameter strainers and
washed up to three times in HBSS w/o. Then samples were centrifuged at 300 RCF
for 5 min and resuspended in HBSS w/o. Finally, the test of cell viability was
performed using Trypan Blue solution (0.4%) while counting cells by an automatic
cell counter (Countess, Thermo Fisher). Single-cell suspension was used immedi-
ately for single-cell RNA-seq experiments.
Single-cell RNA-seq experiments. Single-cell RNA-seq experiments were per-
formed on 6 organoids (2 organoids per condition CTRL (9290 single cells),
Y366Lfs (5199 single cells), and E370K (4095 single cells)) using the Chromium
10X Genomics platform following the manual instructions of the Chromium Single
Cell 3′ v2 Reagent Kit. In brief, 6000 cells per sample were loaded on a Single Cell A
chip, following droplets with single cells and barcoded beads’ generation, com-
plementary DNA synthesis, preamplification, and library preparation. Sequencing-
ready libraries with unique 10X sample index names were pooled at equal ratios
and sequenced paired-end 26 × 8 × 100 base pairs on a HiSeq 2500 Illumina
platform 2 lanes. Base-calling, adaptor trimming, and de-multiplexing were per-
formed using 10X Genomics Cell Ranger 2.0 software. Data are shown in Sup-
plementary Data 1.
Processing, analysis, and graphic display of 10X genomics-based single-cell
RNA-seq data. As quality controls, cells with more than 6000 or less than 200
detected genes, as well as those with mitochondrial transcripts proportion higher
than 10% were excluded. Additional filtering of cells was done based on the pri-
mary cell type prediction by using public human fetal brain sc-RNA-seq data34.
Cells with predicted ‘glycolysis’ identity, as well as other cells in clusters (using
Seurat, obtained for each CO separately) with more than 80% cells with predicted
‘glycolysis’ identity were excluded from the following analysis. Putative non-
neuronal cells were further filtered, by only including cells with predicted radial
glia, IP cells, excitatory neurons or inhibitory neurons, as well as other cells in
clusters with more than 80% of predicted neuronal cells. The remaining cells were
then represented as the normalized similarity spectrum to the gene expression
levels of 237 fetal human brain samples in the BrainSpan database with bulk RNA-
seq data. Pairwise distances between cells were calculated as the Pearson’s corre-
lation distance between their similarity spectrum representations, with which a
kNN-network (k= 20) was constructed. The kNN-network was visualized using
SPRING. The Walktrap community identification algorithm was applied to the
kNN-network to identify cell clusters. Cells in the clusters with dorsal neural
Table 1 List of antibodies used.
Antigen Dilution Vendor Catalog # Lot #
PAX6 1:500 Biolegend PRB-278p B244513
LGALS3BP 1:100 eBioscience BMS146 –
SOX2 1:500 Cell Signaling 27485 2
HOPX 1:1000 Sigma Aldrich HPA030180 B105571
CTIP2 1:500 Abcam ab18465 GR322373-4
SATB2 1:500 Abcam Ab51502 GR2075794
TBR1 1:500 Abcam ab31940 GR3217067-1
LAMININ 1:500 Millipore AB2034 2558444
MAP2 1:500 Sigma Aldrich M4403 035MN4780V
PALS1 1:500 Sigma Aldrich 07-708 H0907
β-CATENIN 1:500 BD Biosciences 610154 76645
PH3 1:500 Millipore 06-570 3113883
ARL13B 1:200 Proteintech 17711-1-AP –
GAPDH 1:6000 Millipore CB1001 2896484
GFP 1:1000 Aves Lab GFP-1020 697986
NESTIN 1:200 Millipore MAB5326 3112610
PAN-CADHERIN Sigma Aldrich C1821 064M4764
CD82 1:250 Santa Cruz sc-1087 J2814
TBR2 1:500 Abcam ab23345 GR33045451
PHALLOIDIN (ACTIN) 1:40 Thermo Fisher A12381 1743642
DoubleCortin (DCX) 1:2000 Millipore AB2253 2787730
NEUN 1:500 Millipore MAB377 2742283
KI67 1:500 DAKO M7248 20017551
FABP7 1:1000 Millipore ABN14 3160120
HA 1:1000 Santa Cruz Sc-7392 K1918
CD81 1:250 Santa Cruz Sc-166029 D0419
Alexa Fluor® 647 Goat Anti-Mouse IgG (H+ L) 1:1000 Life-Technologies A-21235 –
Alexa Fluor® 647 Goat Anti-Rabbit IgG (H+ L) Antibody 1:1000 Life-Technologies A-21244 2086730
Alexa Fluor® 647 Goat Anti-Guinea Pig IgG (H+ L), highly cross-adsorbed 1:1000 Life-Technologies A-21450 2026140
Alexa Fluor® 546 Goat Anti-Mouse IgG1 (γ1) 1:1000 Life-Technologies A- 21123 1722393
Alexa Fluor® 546 Goat Anti-Mouse IgG (H+ L) 1:1000 Life-Technologies A-11003 –
Alexa Fluor® 546 Goat Anti-Rabbit IgG (H+ L) 1:1000 Life-Technologies A-11010 1971417
Alexa Fluor® 546 Goat Anti-Rat IgG (H+ L) 1:1000 Life-Technologies A-11081 –
Alexa Fluor® 488 Goat Anti-Chicken IgG (H+ L) Antibody 1:1000 Life-Technologies A-11039 2079383
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progenitor or neuron signatures were combined as the dorsal forebrain lineage. The
diffusion map algorithm was applied to cells in the dorsal forebrain lineage. The
bRG signature score was calculated by the sum of expression levels of the five bRG
marker genes which are also shown in Supplementary Fig. 4g (TNC, FAM107A,
HOPX, PTPRZ1, LIFR) obtained from the Kriegstein Lab describing outer radial
glia33. The ranks in DC1 were used as pseudotimes. Dorsal forebrain neural cells
were then grouped into three groups based on their pseudotimes: dorsal forebrain
radial glia, IPs, and neurons. To identify genes with DE between dorsal forebrain
neural cells in control COs and LGALS3BP mutant COs, Wilcoxon’s rank-sum test
was applied to each gene for each of the three dorsal forebrain neuronal cell groups.
In each cell group, DE genes were determined as genes with Bonferroni-corrected
p < 0.01 and at least 1.3-fold change of average expression between the two
conditions.
Whole-proteome analysis from COs. COs were washed twice with PBS and
homogenized in ice-cold lysis buffer (1% (v/v) NP40, 1% (w/v) sodium deox-
ycholate, and 1 tablet protease inhibitor (cOmplete™, Mini, EDTA-free protease
inhibitor cocktail, Roche) in 10 mL PBS) using ultrasonication at 40% intensity for
10 s. Lysis was done for 30 min at 4 °C while rotating. The insoluble fraction was
pelletized (10 min, 14,000g, 4 °C) and protein concentration was determined by
bicinchoninic acid assay (BCA, Carl Roth GmbH + Co.). For the next analysis,
200 μg of the total protein was used. Proteins were precipitated by the addition of
900 μL acetone and overnight incubation at −20 °C. The protein pellet was har-
vested by centrifugation at 9000g for 15 min at 4 °C and washed once with 0.5 mL
of ice-cold methanol. Proteins were reconstituted in 200 μL digestion buffer
(20 mM HEPES, pH 7.5, 7 M urea, 2 M thiourea), reduced (0.2 μL 1M DTT,
45 min, 25 °C), and alkylated (2 μL, 30 min, 25 °C, in the dark). The alkylation
reaction was quenched by the addition of 0.8 μL 1M DTT and incubation for
30 min at 25 °C. Proteins were pre-digested with 1 μL LysC (Wako) at 25 °C for 4 h.
Then, 600 μL 50 mM TEAB buffer was added and the proteins were digested
overnight with 1.5 μL sequencing-grade trypsin (0.5 mg/mL, Promega) at 37 °C.
The following day, the samples were acidified with 10 μL formic acid to a pH of
2–3. Peptides were desalted on 50 mg SepPak C18 cartridges (Waters Corp.) on a
vacuum manifold. The cartridges were equilibrated with 1 mL acetonitrile, 1 mL
80% acetonitrile, and 3 mL 0.5% formic acid. The samples were loaded on the
cartridges and subsequently washed with 5 mL 0.5% formic acid. The peptides were
eluted two times with 250 μL 80% acetonitrile and 0.5% formic acid. Samples
were combined and dried by lyophilization. Peptides were reconstituted in 30 μL
1% (v/v) formic acid, prepared for mass spectrometry by filtering through a
membrane filter (Ultrafree-MC and –LC, Durapore PVDF-0.22 μm, Merck Milli-
pore) and transferred into mass vials. Data are shown in Supplementary Data 2.
Secretome analysis from COs. For secretome analysis, culture media (5 mL) was
collected from 60d COs after 4d of conditioning. The medium was cleared from
dead cells and debris by centrifugation at 34g for 5 min and precipitated with
methanol (20 mL) at −20 °C overnight. The precipitated proteins were collected by
centrifugation at maximum speed for 10 min at 4 °C. The supernatant was
removed. The protein pellet was reconstituted in the lysis buffer (1% (v/v) NP40,
1% (w/v) sodium deoxycholate, and protease inhibitors in PBS, 500 µL). Protein
concentration was measured by BCA. Then, 300 µg of the total protein was used for
further Wessel-Flügge precipitation. The total volume of 150 µL of secretome was
completed with 600 µL of methanol, vortexed, 225 µL of chloroform, vortexed, and
finally 450 µL of water, vortexed and sonicated in an ultrasound bath for 8 min.
The upper phase was removed and discarded leaving the precipitated proteins at
the interface intact. After the addition of the 450 µL of methanol, the mixture was
centrifuged at maximum speed for 20 min at RT. The supernatant was removed
and the resulting protein pellet was let dry on air. The protein pellet was recon-
stituted in 400 µL of digestion buffer and subsequently, 200 µL was used for
reduction, alkylation, digestion by trypsin, desalting, and reconstitution of peptides
as described above for whole-proteome analysis. Data are shown in Supplementary
Data 3.
Mass spectrometry. MS analysis was performed on an Orbitrap Fusion instru-
ment coupled to an Ultimate3000 Nano-HPLC via an electrospray easy source (all
from Thermo Fisher Scientific). Samples were loaded on a 2 cm PepMap RSLC C18
trap column (particles 3 µm, 100 A, inner diameter 75 µm, Thermo Fisher Scien-
tific) with 0.1% trifluoroacetic acid (TFA) and separated on a 50 cm PepMap RSLC
C18 column (particles 2 µm, 100 A, inner diameter 75 µm, Thermo Fisher Scien-
tific) constantly heated at 50 °C. The gradient was run from 5% to 32% acetonitrile,
0.1% formic acid during a 152 min method (7 min 5%, 105 min to 22%, 10 min to
32%, 10 min to 90%, 10 min wash at 90%, 10 min equilibration at 5%) at a flow rate
of 300 nL/min. Instrument survey scans (m/z 300-1500) were acquired in the
Orbitrap with a resolution of 120,000 at m/z 200 and the maximum injection time
set to 50 ms (target value 2e5). Most-intense ions of charge states 2–7 were selected
for fragmentation with high-energy collisional dissociation at a collision energy of
30%. The instrument was operated in top speed mode and spectra were acquired in
the ion trap with the maximum injection time set to 50 ms (target value 1e4). The
option to injections for all available parallelizable times was enabled. Dynamic
exclusion of sequenced peptides was set to 60 s. Real-time mass calibration was
based on internally generated fluoranthene ions. Data were acquired using Xcalibur
software version 3.0sp2 (Thermo Fisher Scientific). Raw files were analyzed using
MaxQuant software (1.6.2.10). Searches were performed against the Uniprot
database for Homo sapiens (taxon identifier: 9606, 21st December 2018, including
isoforms). At least two unique peptides were required for protein identification.
False discovery rate determination was carried out using a decoy database and
thresholds were set to 1% FDR both at a peptide-spectrum match and at protein
levels.
Statistical analysis of the MaxQuant result table proteinGroups.txt was done
with Perseus 1.5.1.6. Putative contaminants and reverse hits were removed. Labeled
free quantification intensities were log2-transformed, hits with less than 3 valid
values in each group were removed and −log10(p-values) were obtained by a two-
sided two samples’ Student’s t-test over replicates with the initial significance level
of p= 0.05 adjustment by the multiple testing correction methods of Benjamini
and Hochberg (FDR= 0.05), the −log10 of p-values were plotted by volcano plot
function. Final volcano plots were edited in Origin.
GO Term analysis. For GO Term analysis of proteins or genes significantly
downregulated or upregulated in the proteome, secretome or scRNA-seq of control
and mutant COs were used to identify overrepresented functional groups and
single proteins/genes falling into those with Panther, choosing Homo sapiens as
species and searched for enrichment of Biological processes or cellular component
complete using Fisher’s exact test and FDR threshold of 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data supporting the findings described in this paper are available in the article and in
the Supplementary Information, and from the corresponding authors upon reasonable
request. Data illustrated in Supplementary Fig. 1a are obtained from34 and cited in this
paper. For the New Zealand-based study on human individuals, unrestricted sharing of
individual exome sequences was not approved by the New Zealand Ethics Review
Committee on confidentiality grounds. Please contact Prof. Stephen P. Robertson (co-
corresponding author) for access request. A response will be given within 1 month upon
request. The bulk RNA-seq data used in this study have been deposited in the Gene
Expression Omnibus under accession number GSE181405. The scRNA-seq data used in
this study have been deposited in the ArrayExpress under accession number E-MTAB-
10485. The mass spectrometry proteomics data and mass spectrometry secretomic data
have been deposited to the ProteomeXchange Consortium via the PRIDE84 partner
repository with the dataset identifier PXD015878. There is no restriction for data access
in all the above. Source data are provided with this paper (Supplementary Data 6). Web
resources used in this paper are listed here: DECIPHER, https://decipher.sanger.ac.uk/
scRNA-sequencing data from human fetal cortex https://cells.ucsc.edu/?ds=cortex-dev
gnomAD Browser, v.r2.0.2, http://gnomad.broadinstitute.org/ Source data are provided
with this paper.
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